Canadian Cancer Trials Group Bulletins

General


Trial Closed to Accrual

Canadian Cancer Trials Group CEC.1 / ECOG 26053_22054 / RTOG 0834 trial - A Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma - met its accrual goal and was closed to further recruitment on September 15, 2015. Patients that are currently registered, but not randomized, are able to enter the trial when eligibility is confirmed.

Nine Canadian sites were activated and contributed 42 registered patients, of which 22 were randomized out of 748 total patients.

Thank you to everyone who has supported this important intergroup trial for brain cancer.